ALK and non-small cell lung carcinoma: During the last two decades progress has been made in developing targeted agents for the small subgroup of oncogene-addicted NSCLC, including EGFR mutated and ALK translocated patients, while cytotoxic chemotherapy has represented the only available treatment for all unselected NSCLC patients [2] until the introduction of immunotherapy.